Menu Search
Equities

Immutep Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
YP1A:STU

Immutep Ltd

Actions
  • Price (EUR)2.20
  • Today's Change-0.02 / -0.90%
  • Shares traded0.00
  • 1 Year change+14.58%
  • Beta1.7747
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

  • Revenue in USD (TTM)41.61k
  • Net income in USD-42.54m
  • Incorporated1987
  • Employees--
  • Location
    Immutep LtdPlaza Building, L 12 95 Pitt StSYDNEY 2000AustraliaAUS
  • Phone+61 28315-7003
  • Fax+61 28569-1880
  • Websitehttps://www.immutep.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.